- Home
- EDIT vs LXEO Comparison
EDIT vs LXEO Comparison
Compare EDIT & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EDIT | LXEO |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.8M | 348.7M |
| IPO Year | 2016 | 2023 |
Fundamental Metrics
Financial Performance| Metric | EDIT | LXEO |
|---|---|---|
| Price | $2.69 | $3.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $5.30 | ★ $18.44 |
| AVG Volume (30 Days) | ★ 2.3M | 774.8K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 37.50 | ★ 39.81 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $31,937,000.00 | $654,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 132.64 | N/A |
| 52 Week Low | $1.66 | $3.99 |
| 52 Week High | $4.54 | $10.99 |
Technical Indicators
Market Signals| Indicator | EDIT | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 31.52 |
| Support Level | N/A | N/A |
| Resistance Level | N/A | $5.38 |
| Average True Range (ATR) | 0.00 | 0.22 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.